Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2010

01-02-2010 | Original Article

Abdominal Sonographic Changes After Antibody to Tumor Necrosis Factor (Anti-TNF) Alpha Therapy in Crohn’s Disease

Authors: José María Paredes, Tomás Ripollés, Xavier Cortés, María Jesús Martínez, María Barrachina, Fernando Gómez, Eduardo Moreno-Osset

Published in: Digestive Diseases and Sciences | Issue 2/2010

Login to get access

Abstract

Prospective study carried out on 24 consecutive patients with Crohn’s Disease, using sonography to assess changes caused by biological therapy and its relationship with the clinical-biological response. The Crohn’s Disease Activity Index, the plasma concentration of C-reactive protein and abdominal sonograms (to assess the thickness and Doppler flow grade of the bowel wall and to detect the presence of any complications) were carried out one week prior to the induction treatment and two weeks after. The biological therapy induced remission or a partial response in 46% and 25% of the patients, respectively. It also caused a significant reduction in the thickness of the bowel wall (P = 0.005) and Doppler flow (P = 0.02), leading to the disappearance of complications in 50% of the patients. Sonographic changes were significantly more marked in patients who achieved some type of clinical-biological response, in such a way that sonograms were improved in 65% (P = 0.001) and complications disappeared in 100% of patients (P = 0.005) compared to those patients who did not respond to treatment. However, sonographic normality was only achieved in five out of 17 (29%) reactive patients (P  = 0.27). This fact may support the use of sonography as a technique for optimizing the biological treatment of Crohn’s Disease.
Literature
2.
go back to reference Clark M, Colombel JF, Feagan BC, et al. American Gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, june 21–23, 2006. Gastroenterology. 2007;133:312–339. doi:10.1053/j.gastro.2007.05.006.CrossRefPubMed Clark M, Colombel JF, Feagan BC, et al. American Gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, june 21–23, 2006. Gastroenterology. 2007;133:312–339. doi:10.​1053/​j.​gastro.​2007.​05.​006.CrossRefPubMed
3.
6.
go back to reference Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistent of Crohn’s disease associated fistulas alter infliximab treatment, irrespective of clinical response. Dis Colon Rectum. 2002;45:39–45. doi:10.1007/s10350-004-6111-6.CrossRefPubMed Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, Meuwissen SG. Endosonographic evidence of persistent of Crohn’s disease associated fistulas alter infliximab treatment, irrespective of clinical response. Dis Colon Rectum. 2002;45:39–45. doi:10.​1007/​s10350-004-6111-6.CrossRefPubMed
8.
go back to reference Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn’s disease. Dis colon Rectum. 2002;45:771–775.CrossRefPubMed Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn’s disease. Dis colon Rectum. 2002;45:771–775.CrossRefPubMed
10.
go back to reference Spalinger J, Patriquin H, Miron MC, et al. Doppler US in patients with Crohn disease: vessel density in the diseased bowel reflects disease activity. Radiology. 2000;217:787–791.PubMed Spalinger J, Patriquin H, Miron MC, et al. Doppler US in patients with Crohn disease: vessel density in the diseased bowel reflects disease activity. Radiology. 2000;217:787–791.PubMed
12.
go back to reference Haber HP, Busch A, Ziebach R, Dette S, Ruck P, Stern M. US findings correspond to clinical, endoscopic and histologic findings in inflammatory bowel disease and other enterocolitides. J Ultrasound Med. 2002;21:375–382.PubMed Haber HP, Busch A, Ziebach R, Dette S, Ruck P, Stern M. US findings correspond to clinical, endoscopic and histologic findings in inflammatory bowel disease and other enterocolitides. J Ultrasound Med. 2002;21:375–382.PubMed
13.
go back to reference Guidi L, De Franco A, De Vitis I, et al. Contrast-enhanced ultrasonography with Sonovue alter infliximab therapy in Crohn’s disease. Eur Rev Med Pharmacol Sci. 2006;10:23–26.PubMed Guidi L, De Franco A, De Vitis I, et al. Contrast-enhanced ultrasonography with Sonovue alter infliximab therapy in Crohn’s disease. Eur Rev Med Pharmacol Sci. 2006;10:23–26.PubMed
19.
go back to reference Ruess L, Nussbaum AR, Bulas D, et al. Inflammatory bowel disease in children and young adults: correlation of sonographic and clinical parameters during treatment. AJR. 2000;175:79–84.PubMed Ruess L, Nussbaum AR, Bulas D, et al. Inflammatory bowel disease in children and young adults: correlation of sonographic and clinical parameters during treatment. AJR. 2000;175:79–84.PubMed
20.
go back to reference Ripollés T, Martínez MJ, Barrachina MM. Crohn’s disease and color Doppler sonography: Response to treatment and its relationship with long-term prognosis. J Clin Ultrasound. 2008;36:267–272. doi:10.1002/jcu.20423.CrossRefPubMed Ripollés T, Martínez MJ, Barrachina MM. Crohn’s disease and color Doppler sonography: Response to treatment and its relationship with long-term prognosis. J Clin Ultrasound. 2008;36:267–272. doi:10.​1002/​jcu.​20423.CrossRefPubMed
21.
go back to reference Maconi G, Sampietro GM, Cristaldi M, et al. Preoperative characteristics and postoperative behaviour of bowel wall on risk of recurrence after conservative surgery in Crohn’s disease. A prospective study. Ann Surg. 2001;233:345–352. doi:10.1097/00000658-200103000-00007.CrossRefPubMed Maconi G, Sampietro GM, Cristaldi M, et al. Preoperative characteristics and postoperative behaviour of bowel wall on risk of recurrence after conservative surgery in Crohn’s disease. A prospective study. Ann Surg. 2001;233:345–352. doi:10.​1097/​00000658-200103000-00007.CrossRefPubMed
22.
go back to reference Maconi G, Parente F, Bollani S, Cesana B, Bianchi Porro G. Abdominal ultrasound in the assessment of extent and activity of Crohn’s disease: clinical significance and implication of bowel wall thickening. Am J Gastroenterol. 1996;91:1604–1609.PubMed Maconi G, Parente F, Bollani S, Cesana B, Bianchi Porro G. Abdominal ultrasound in the assessment of extent and activity of Crohn’s disease: clinical significance and implication of bowel wall thickening. Am J Gastroenterol. 1996;91:1604–1609.PubMed
23.
go back to reference Serra C, Menozzi G, Morselli Labate AM, et al. Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn’s disease patients using a low-mechanical index real-time sacanning technique with a second generation ultrasound contrast agent. Eur J Radiol. 2007;62:114–121. doi:10.1016/j.ejrad.2006.11.027.CrossRefPubMed Serra C, Menozzi G, Morselli Labate AM, et al. Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn’s disease patients using a low-mechanical index real-time sacanning technique with a second generation ultrasound contrast agent. Eur J Radiol. 2007;62:114–121. doi:10.​1016/​j.​ejrad.​2006.​11.​027.CrossRefPubMed
Metadata
Title
Abdominal Sonographic Changes After Antibody to Tumor Necrosis Factor (Anti-TNF) Alpha Therapy in Crohn’s Disease
Authors
José María Paredes
Tomás Ripollés
Xavier Cortés
María Jesús Martínez
María Barrachina
Fernando Gómez
Eduardo Moreno-Osset
Publication date
01-02-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-0759-7

Other articles of this Issue 2/2010

Digestive Diseases and Sciences 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.